Cargando…

FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy

BACKGROUND: The role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in prostate cancer (PCa) has not been well defined yet. Because high-grade PCa tends to exhibit increased glycolytic rate, FDG-PET/CT could be useful in this setting. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Beauregard, Jean-Mathieu, Blouin, Annie-Claude, Fradet, Vincent, Caron, André, Fradet, Yves, Lemay, Claude, Lacombe, Louis, Dujardin, Thierry, Tiguert, Rabi, Rimac, Goran, Bouchard, Frédérick, Pouliot, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352558/
https://www.ncbi.nlm.nih.gov/pubmed/25889163
http://dx.doi.org/10.1186/s40644-015-0038-0
_version_ 1782360479422742528
author Beauregard, Jean-Mathieu
Blouin, Annie-Claude
Fradet, Vincent
Caron, André
Fradet, Yves
Lemay, Claude
Lacombe, Louis
Dujardin, Thierry
Tiguert, Rabi
Rimac, Goran
Bouchard, Frédérick
Pouliot, Frédéric
author_facet Beauregard, Jean-Mathieu
Blouin, Annie-Claude
Fradet, Vincent
Caron, André
Fradet, Yves
Lemay, Claude
Lacombe, Louis
Dujardin, Thierry
Tiguert, Rabi
Rimac, Goran
Bouchard, Frédérick
Pouliot, Frédéric
author_sort Beauregard, Jean-Mathieu
collection PubMed
description BACKGROUND: The role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in prostate cancer (PCa) has not been well defined yet. Because high-grade PCa tends to exhibit increased glycolytic rate, FDG-PET/CT could be useful in this setting. The aim of this study was to assess the value of FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade PCa at biopsy. METHODS: Fifty-four patients with a Gleason sum ≥8 PCa at biopsy underwent FDG-PET/CT as part of the staging workup. Thirty-nine patients underwent radical prostatectomy (RP) and pelvic lymph node (LN) dissection, 2 underwent LN dissection only, and 13 underwent non-surgical treatments. FDG-PET/CT findings from clinical reports, blinded reading and quantitative analysis were correlated with clinico-pathological characteristics at RP. RESULTS: Suspicious foci of increased FDG uptake were found in the prostate, LNs and bones in 44, 13 and 6% of patients, respectively. Higher clinical stage, post-RP Gleason sum and pattern, and percentage of cancer involvement within the prostate were significantly associated with the presence of intraprostatic FDG uptake (IPFU) (P < 0.05 in all cases). Patients without IPFU who underwent RP were downgraded to Gleason ≤7 in 84.6% of cases, as compared to 30.8% when IPFU was reported (P = 0.003). Qualitative and quantitative IPFU were significantly positively correlated with post-RP Gleason pattern and sum, and pathological T stage. Absence and presence of IPFU were associated with a median 5-year cancer-free survival probability of 70.2 and 26.9% (P = 0.0097), respectively, using the CAPRA-S prognostic tool. CONCLUSION: These results suggest that, among patients with a high-grade PCa at biopsy, FDG-PET/CT could improve pre-treatment prognostic stratification by predicting primary PCa pathological grade and survival probability following RP.
format Online
Article
Text
id pubmed-4352558
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43525582015-03-09 FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy Beauregard, Jean-Mathieu Blouin, Annie-Claude Fradet, Vincent Caron, André Fradet, Yves Lemay, Claude Lacombe, Louis Dujardin, Thierry Tiguert, Rabi Rimac, Goran Bouchard, Frédérick Pouliot, Frédéric Cancer Imaging Research Article BACKGROUND: The role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in prostate cancer (PCa) has not been well defined yet. Because high-grade PCa tends to exhibit increased glycolytic rate, FDG-PET/CT could be useful in this setting. The aim of this study was to assess the value of FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade PCa at biopsy. METHODS: Fifty-four patients with a Gleason sum ≥8 PCa at biopsy underwent FDG-PET/CT as part of the staging workup. Thirty-nine patients underwent radical prostatectomy (RP) and pelvic lymph node (LN) dissection, 2 underwent LN dissection only, and 13 underwent non-surgical treatments. FDG-PET/CT findings from clinical reports, blinded reading and quantitative analysis were correlated with clinico-pathological characteristics at RP. RESULTS: Suspicious foci of increased FDG uptake were found in the prostate, LNs and bones in 44, 13 and 6% of patients, respectively. Higher clinical stage, post-RP Gleason sum and pattern, and percentage of cancer involvement within the prostate were significantly associated with the presence of intraprostatic FDG uptake (IPFU) (P < 0.05 in all cases). Patients without IPFU who underwent RP were downgraded to Gleason ≤7 in 84.6% of cases, as compared to 30.8% when IPFU was reported (P = 0.003). Qualitative and quantitative IPFU were significantly positively correlated with post-RP Gleason pattern and sum, and pathological T stage. Absence and presence of IPFU were associated with a median 5-year cancer-free survival probability of 70.2 and 26.9% (P = 0.0097), respectively, using the CAPRA-S prognostic tool. CONCLUSION: These results suggest that, among patients with a high-grade PCa at biopsy, FDG-PET/CT could improve pre-treatment prognostic stratification by predicting primary PCa pathological grade and survival probability following RP. BioMed Central 2015-03-03 /pmc/articles/PMC4352558/ /pubmed/25889163 http://dx.doi.org/10.1186/s40644-015-0038-0 Text en © Beauregard et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Beauregard, Jean-Mathieu
Blouin, Annie-Claude
Fradet, Vincent
Caron, André
Fradet, Yves
Lemay, Claude
Lacombe, Louis
Dujardin, Thierry
Tiguert, Rabi
Rimac, Goran
Bouchard, Frédérick
Pouliot, Frédéric
FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy
title FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy
title_full FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy
title_fullStr FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy
title_full_unstemmed FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy
title_short FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy
title_sort fdg-pet/ct for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352558/
https://www.ncbi.nlm.nih.gov/pubmed/25889163
http://dx.doi.org/10.1186/s40644-015-0038-0
work_keys_str_mv AT beauregardjeanmathieu fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy
AT blouinannieclaude fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy
AT fradetvincent fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy
AT caronandre fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy
AT fradetyves fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy
AT lemayclaude fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy
AT lacombelouis fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy
AT dujardinthierry fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy
AT tiguertrabi fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy
AT rimacgoran fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy
AT bouchardfrederick fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy
AT pouliotfrederic fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy